首页> 外文期刊>Endocrine journal >Mutation Analysis Of Rap1 Gene In Papillary Thyroid Carcinomas
【24h】

Mutation Analysis Of Rap1 Gene In Papillary Thyroid Carcinomas

机译:乳头状甲状腺癌Rap1基因的突变分析

获取原文
获取原文并翻译 | 示例
       

摘要

In human papillary thyroid carcinomas (PTCs), the genetic alterations of RET/PTC, RAS or BRAF account for about 60-70% of cases with practically no overlap, providing strong genetic evidence that constitutive active signaling along MAPK pathway is critical for PTC development. In the remaining 30-40% of the cases, the oncogenes are still unknown. RAP1 is a member of the RAS family of small G proteins transmitting signals from the TSH-R to MAPK pathway using cAMP-dependent mechanism in thyroid cells. RAP1 was shown to have both mitogenic and tumorigenic properties in certain systems; however, the potential role of RAP1 mutation in thyroid carcinogenesis has yet to be elucidated. In this study, we analyzed the mutational status of RAP1 gene in 36 Russian patients with PTCs without RET/ PTC rearrangement, BRAF mutation or RAS mutation. No mutations in either RAP1A or RAP1B genes were found. These results suggest that RAP1 mutation does not play an important role in PTC pathogenesis.
机译:在人乳头状甲状腺癌(PTC)中,RET / PTC,RAS或BRAF的基因改变约占病例的60-70%,几乎没有重叠,这提供了强有力的遗传学证据,表明沿着MAPK途径的组成性主动信号传导对PTC的发展至关重要。 。在其余30-40%的病例中,致癌基因仍是未知的。 RAP1是RAS小G蛋白家族的成员,它利用cAMP依赖性机制在甲状腺细胞中将信号从TSH-R传递到MAPK途径。 RAP1在某些系统中显示出有丝分裂和致瘤特性。然而,尚未阐明RAP1突变在甲状腺癌变中的潜在作用。在这项研究中,我们分析了俄罗斯36例无RET / PTC重排,BRAF突变或RAS突变的PTC患者中RAP1基因的突变状态。在RAP1A或RAP1B基因中均未发现突变。这些结果表明,RAP1突变在PTC发病机理中不发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号